share_log

Allarity Therapeutics | 10-Q: Q1 2024 Earnings Report

Allarity Therapeutics | 10-Q: Q1 2024 Earnings Report

Allarity Therapeutics | 10-Q:2024財年一季報
美股SEC公告 ·  05/14 16:50

Moomoo AI 已提取核心訊息

Allarity Therapeutics, Inc. (Allarity), a clinical-stage biopharmaceutical company, reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $3.8 million, compared to a net loss of $3.4 million for the same period in the previous year. Research and development expenses increased by $743 thousand, primarily due to higher manufacturing and supplies expenses for their lead drug candidate, Stenoparib. General and administrative expenses decreased by $171 thousand, mainly due to lower insurance and legal costs. Other income for the quarter was $393 thousand, largely from a fair value adjustment to derivative and warrant liabilities. As of March 31, 2024, Allarity had cash reserves of $312 thousand and an accumulated deficit of $98.3 million. The company's cash position is not sufficient to fund...Show More
Allarity Therapeutics, Inc. (Allarity), a clinical-stage biopharmaceutical company, reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $3.8 million, compared to a net loss of $3.4 million for the same period in the previous year. Research and development expenses increased by $743 thousand, primarily due to higher manufacturing and supplies expenses for their lead drug candidate, Stenoparib. General and administrative expenses decreased by $171 thousand, mainly due to lower insurance and legal costs. Other income for the quarter was $393 thousand, largely from a fair value adjustment to derivative and warrant liabilities. As of March 31, 2024, Allarity had cash reserves of $312 thousand and an accumulated deficit of $98.3 million. The company's cash position is not sufficient to fund operations for the next twelve months, and they plan to seek additional funding through public equity, private equity, debt financing, or collaboration partnerships. Allarity has also been involved in several significant transactions, including a reverse stock split and the sale of common shares through an at-the-market equity offering program, which raised net proceeds of $20,610 from the sale of 14,352,186 shares of common stock post-quarter-end. The company's future plans include continuing the development of Stenoparib and seeking additional capital to fund operations and planned capital expenditures.
臨床階段生物製藥公司Allarity Therapeutics,Inc.(簡稱Allarity)宣佈其2024年3月31日結束的季度財務業績。該公司淨虧損380萬美元,而去年同期淨虧損340萬美元。研發費用增加了74.3萬美元,主要是由於其主要藥物候選Stenoparib的製造和供應成本較高。總部和管理費用減少了17.1萬美元,主要是由於保險和法律費用降低。本季度其他收入爲39.3萬美元,主要來自對衍生品和認股權證負債的公允價值調整。截至2024年3月31日,Allarity現金儲備爲31.2萬美元,累計赤字爲9830萬美元。公司的現金位置不足以爲未來12個月的運營提供資金,他們計劃通過公共股...展開全部
臨床階段生物製藥公司Allarity Therapeutics,Inc.(簡稱Allarity)宣佈其2024年3月31日結束的季度財務業績。該公司淨虧損380萬美元,而去年同期淨虧損340萬美元。研發費用增加了74.3萬美元,主要是由於其主要藥物候選Stenoparib的製造和供應成本較高。總部和管理費用減少了17.1萬美元,主要是由於保險和法律費用降低。本季度其他收入爲39.3萬美元,主要來自對衍生品和認股權證負債的公允價值調整。截至2024年3月31日,Allarity現金儲備爲31.2萬美元,累計赤字爲9830萬美元。公司的現金位置不足以爲未來12個月的運營提供資金,他們計劃通過公共股權、私募股權、債務融資或合作伙伴關係尋求額外資金。Allarity還參與了幾項重要交易,包括倒向股票分割和通過現場股票發行計劃出售普通股,該計劃於季度結束後籌集了206.1萬美元的淨收益,通過出售14352186股普通股。該公司的未來計劃包括繼續開發Stenoparib並尋求額外資金以資助運營和計劃的資本支出。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息